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INTRODUCTION
It has been estimated that almost 5.7 million people in Latin 
America have glaucoma, principally the open-angle sub ty pe, and 
that this number will increase to approximately 8 million people by 
2020(1). The burden of glaucoma is substantial in La tin America, where 
it is one of the leading causes of blindness or visual impairment in 
both adults and children(2-9) and has a significant negative impact 
on quality of life(10). The burden of glaucoma may be higher in Latin 
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ABSTRACT 
Purpose: The aim of this research was to assess the level of agreement among 
glaucoma experts in Latin America on key practices related to treatment and 
diagnosis of glaucoma. 
Methods: An online questionnaire was sent to a multinational panel of glaucoma 
experts. The questionnaire contained 107 statements on the medical treatment 
(Part 1) and diagnosis (Part 2) of glaucoma, and was developed in Spanish and 
translated into English. Agreement was defined as ≥70% of respondents. 
Results: Fifty participants from 14 countries completed the questionnaire. For the 
medical treatment of glaucoma, nearly all respondents (98% or greater) confirmed 
that medical treatment as first-line therapy is preferred to surgery, prostaglandin 
analogs are the medication of first choice for primary open-angle glaucoma (POAG), 
longitudinal monitoring of efficacy should include intraocular pressure, structural 
and functional status, as well as if patients’ quality of life is impaired by the high cost 
of medication. For the diagnosis of glaucoma section, all respondents confirmed 
that, after initial examination, gonioscopy should be repeated over time, standard 
automated perimetry is the most important functional examination for diagnosis 
and monitoring of primary open-angle glaucoma, central corneal thickness is 
important in assessment of glaucoma, and computerized imaging tests help in 
clinical evaluation of optic disc. 
Conclusions: This survey shows a high level of agreement on most aspects of 
glaucoma diagnosis and treatment among Latin American glaucoma experts. 
Areas of disagreement highlight the need for further evidence or education. These 
findings will be useful for guiding future efforts to optimize glaucoma practice 
by clinicians in Latin America.
Keywords: Glaucoma/diagnosis; Glaucoma/therapy; Questionnaires; Humans
RESUMO
Objetivo: Avaliar o nível de concordância entre os especialistas de glaucoma na 
América Latina sobre as práticas mais importantes relacionadas ao tratamento e 
diagnóstico de glaucoma. 
Métodos: Um questionário digital foi enviado a um painel multinacional de espe-
cialistas em glaucoma. O questionário continha 107 declarações sobre o tratamento 
médico (Parte 1) e diagnóstico (Parte 2) de glaucoma, e foi desenvolvido em espanhol 
e traduzido para o Inglês. Concordância foi definida como ≥ 70% dos entrevistados. 
Resultados: Cinquenta participantes de 14 países responderam ao questionário. 
Para o tratamento médico de glaucoma, quase todas as respostas (98% ou mais), 
confirmaram que o tratamento médico como terapia de primeira linha é preferido 
para a cirurgia, os análogos das prostaglandinas são os medicamentos de primeira 
escolha para o glaucoma primário de ângulo aberto (GPAA), a monitoração longitu-
dinal eficácia deve incluir a pressão intraocular o estado estrutural e funcional além 
da qualidade de vida do paciente ser prejudicada pelo alto custo da medicação. Para 
a seção sobre o diagnóstico de glaucoma, todos os entrevistados confirmaram que, 
após análise inicial, a gonioscopia deve ser repetida ao longo do tempo, a perimetria 
automatizada padrão é o exame funcional mais importante para o diagnóstico e 
monitoramento do glaucoma primário de ângulo aberto, a espessura corneana central 
é importante na avaliação do glaucoma e exames de imagem computadorizados 
ajudam na avaliação clínica do disco óptico. 
Conclusões: Este estudo mostra um alto nível de concordância na maioria dos as-
pectos do diagnóstico e tratamento de glaucoma entre os especialistas em glaucoma 
latino-americanos. Áreas de desacordo destacam a necessidade de novas evidências 
ou educação. Estes resultados serão úteis para orientar futuros esforços na otimização 
de práticas em relação ao glaucoma por médicos da América Latina.
Descritores: Glaucoma/diagnóstico; Glaucoma/tratamento; Questionários; Humanos
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America than in more developed regions because poverty acts as a 
barrier to effective diagnosis and treatment(11,12), resulting in a high 
pro portion of patients presenting with advanced disease. 
While diagnostic and treatment strategies for glaucoma have 
evolved over the years, many gaps remain in our understanding of 
optimal practice for diagnosis and management. Moreover, manage-
ment practices differ between and even within countries, depending 
on the health infrastructure. Recently, attempts have been made 
by the World Glaucoma Association (WGA) to provide guidance on 
international best practices in glaucoma diagnosis and treatment. To 
this end, the WGA has developed a number of consensus statements, 
providing guidance on a range of issues including structure and func-
tion in the diagnosis of glaucoma(13), closed-angle glaucoma (CAG), 
intraocular pressure (IOP), and medical therapy(14).
Typically, consensus statements on glaucoma management prac -
tices have been developed by a restricted panel working in two 
phases: first surveying participants for their agreement on particular 
questions relating to clinical practice, and then meeting to share the 
results of the survey, before asking panelists to rate the questions 
again(15,16). However, considerable insight into the level of agreement 
among clinical experts can also be gained by administration of a sin-
gle survey(17-19), which can then guide the development of guidelines 
or highlight the need for further research or education on a national 
or regional basis.
The Latin American Glaucoma Society (LAGS) developed a survey 
among key clinical experts in the region to determine the level of 
agreement on key practices related to the treatment and diagnosis 
of glaucoma, including region-specific issues in Latin America. Here 
we report the methodology and findings of this research initiative.
MeThODS
Questionnaire preparation
A multinational panel of ophthalmology experts developed a 
two-part questionnaire: Part 1 was on the medical treatment of glau-
coma and Part 2 was on the diagnosis of glaucoma. The questionnaire 
consisted of a number of statements; respondents were asked to 
rate their agreement with each statement using various scales. The 
statements were developed by the panel based on an analysis of the 
medical literature, a review of existing WGA consensus statements, 
and their own clinical experience. Relevant medical literature was 
identified by means of a PubMed search undertaken in September 
2009. The following search terms were used: treatment strategies, 
target IOP, general concepts about medical therapy, antiglaucoma 
drugs, adverse events, neuroprotection, compliance, specific aspects 
of treatment in Latin America and generic/copy medications, general 
aspects of glaucoma diagnosis, clinical examination of the optic 
nerve, examination of the nerve fiber layer, diagnosis in primary 
closed-an gle glaucoma (PCAG), gonioscopy, functional examination, 
IOP, and structural examination by imaging. At the time of survey 
development, WGA consensus statements were available for diag-
nosis(13) and IOP, but not for glaucoma treatment. 
The survey development panel drafted 107 statements relating 
to the medical therapy or diagnosis of glaucoma. The full results of 
the survey are presented in this paper (see Appendix). The ques-
tionnaire included open-ended and closed-ended questions (yes/
no, multiple choice, rating scale).
survey 
The survey was developed in Spanish, translated into English, and 
uploaded to an online survey tool. An email invitation to complete 
the survey was sent to 50 individuals from geographically diverse 
parts of the region: 31 were members of the LAGS and 19 were others 
who were identified by LAGS members as Latin American ophthal-
mologists with particular expertise in the field of glaucoma diagnosis 
and treatment. The survey was completed between October 2009 
and April 2010. 
analysis
Upon receipt of the questionnaire results, the level of agreement 
or disagreement for each statement was calculated by assessing 
the percentage of respondents giving each answer. Consensus was 
defined a priori as agreement in >70% of the group. For Likert scale 
questions, “strongly agree” and “agree”, “strongly disagree” and “disa-
gree” were pooled together. Combining scores for the purposes of 
categorization has been used in previous similar studies, in both glau-
coma(15,16) and other indications(20). Internal consistency for each part 
(medical treatment and diagnosis of glaucoma) and for each subca-
tegory/topic, as well as overall consistency, was measured using a 
standardized Cronbach’s coefficient alpha. A Cronbach’s coefficient 
alpha of ≥0.65 was considered to indicate internal consistency.
ReSUlTS
All 50 participants returned the survey and 48 participants com-
pleted all questions in the survey. Survey respondents were from Bra-
zil (n=16), Argentina (n=9), Colombia (n=5), Mexico (n=4), Chile (n=3), 
Peru (n=3), Venezuela (n=3), Costa Rica (n=1), Guatemala (n=1), Ecua-
dor (n=1), Paraguay (n=1), Puerto Rico (n=1), Uruguay (n=1), and USA 
(n=1). Most participants (n=30) worked in both private practice and 
the public sector, but 17 worked solely in private practice and 1 so-
lely in the public sector; 2 participants did not answer the question 
on clinical practice type. Survey respondents had been in clinical 
practice for between 2 and 50 years (mean ± standard deviation [SD] 
22.68 ± 10.75 years).
Overall, the panel found agreement in 75 (70.1%) of 107 state-
ments and no agreement in 32 (29.9%) (Tables 1 and 2). We will now 
highlight the results of the survey; for full results, please refer to the 
Appendix. In Part 1, medical treatment of glaucoma, respondents 
unanimously agreed that knowing the hypotensive efficacy of diffe-
rent glaucoma medications was essential (question 15). Examples 
of medical therapy questions on which no agreement was reached 
were those related to achieving the greatest possible reduction in IOP 
(question 10), what constitutes the maximal number of medications 
(question 19), whether prostaglandin analogs reduce IOP in open-an-
gle glaucoma (OAG) with peripheral anterior synechiae (question 25), 
the maximum number of daily doses to maintain patient adherence 
(question 37), and whether generic medications are bioequivalent 
and interchangeable (question 46).
In Part 2 on glaucoma diagnosis, respondents unanimously agreed 
on four issues: that after initial examination, gonioscopy should be 
performed in all patients with glaucoma or suspected glaucoma and 
repeated over time (questions 83 and 84), that standard automated 
perimetry (SAP) is the most important functional examination for 
the diagnosis and monitoring of primary open-angle glaucoma 
(POAG) (question 88), that central corneal thickness is important in 
the assessment of glaucoma or suspected glaucoma (question 92), 
and that computerized imaging helps in clinical evaluation of the 
optic disc (question 103). Examples of diagnostic questions where 
no agreement was reached were those relating to initial assessment 
of the optic nerve fiber layer (question 77), the most useful tonome-
tric method to use in suspect glaucoma patients (question 98), use 
of the Pascal tonometer (question 95) or ocular response analyzer 
(ORA) (question 96) in preference to the Goldmann tonometer, tests 
for early detection of glaucoma damage (question 105), and optimal 
method of analyzing progression of nerve fiber layer (question 107). 
Consistency scores for the full 107-question survey were 
0.675619 for Part 1 on medical treatment of glaucoma, 0.640498 for 
Part 2 on diagnosis of glaucoma, and 0.675030 overall, indicating a 
general consistency in responses.
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Table 1. Medical treatment of glaucoma consensus statements (questions with 70% or greater agreement) 
Question  
No
No of 
responses Summary n (%) 
Treatment strategies
08 50 Medical treatment is preferred first-line (over surgery) 49 (098.0%)
Target intraocular pressure
09 50 Target IOP is a useful concept 48 (096.0%)
14 50 Target IOP concept is dynamic and must be individualized 48 (096.0%)
11 50 Target IOP must be determined for each patient 48 (096.0%)
12 50 IOP should be at stable target levels for over 24 hours 45 (090.0%)
13 50 Ideal medication decreases IOP, has minimal ocular side effects, and is affordable 47 (094.0%)
General concepts 
15 50 Knowledge of hypotensive efficacy of medication is essential 50 (100.0%)
18 50 If hypotensive effect is <10%, medication is replaced with another 44 (088.0%)
21 50 Medication of first choice for POAG is prostaglandin analogs 49 (098.0%)
16 50 Longitudinal monitoring of efficacy should include IOP, structural and functional status 49 (098.0%)
17 50 Hypotensive efficacy, with reasonable safety, is more important for choosing medication 39 (078.0%)
20 50 Chronic use of benzalkonium chloride adversely affects prognosis for surgery 47 (094.0%)
24 50 There are no significant clinical differences in hypotensive efficacy between different prostaglandin analogs 38 (076.0%)
26 50 There are no significant clinical differences in hypotensive efficacy between different carbonic anhydrase inhibitors 43 (086.0%)
22 50 Prostaglandin analogs have a significantly higher hypotensive efficacy than β-blockers 50 (100.0%)
Adverse events 
31 50 β-blockers have the best LOCAL safety profile 42 (084.0%)
32 50 Prostaglandin analogs have the best SYSTEMIC safety profile 45 (090.0%)
27 50 Hyperemia associated with the use of some glaucoma treatment medications is related to a mild inflammatory response 36 (072.0%)
Neuroprotection 
33 50 No systemic medication has a proven neuroprotective action in humans 43 (086.0%)
34 50 No topical medication has a proven neuroprotective action in humans in addition to IOP lowering 46 (092.0%)
Compliance 
39 50 Quality of life is impaired by the high cost of medication 48 (096.0%)
35 50 Lack of patient compliance is the main cause of glaucoma treatment failure 37 (074.0%)
36 50 Compliance with medical therapy is a major impediment affecting approximately 50% of patients 40 (080.0%)
41 50 Education for patients about their illness is critical for improving treatment compliance 48 (096.0%)
Specific aspects of treatment in latin America
44 50 I agree with the use of prostaglandin/timolol combinations in Latin America 42 (084.0%)
42 50 Glaucoma therapy is unaffordable for most patients in Latin America 36 (072.0%)
45 50 It is not important for prostaglandin/timolol combinations to be approved by the FDA 35 (070.0%)
Generic/copy drugs
47 49 Copy medications are not bioequivalent and interchangeable 40 (081.6%)
50 49 We as a group should be doing something about access to quality medical therapy 47 (095.9%)
51 49 I would participate in a multicenter comparative study of original medications versus generic/“copy” medications designed 
by the LAGS
46 (093.9%)
FDA= Food and Drug Administration; IOP= intraocular pressure; LAGS= Latin American Glaucoma Society; POAG= primary open-angle glaucoma.
DISCUSSION
To our knowledge, this is the first region-wide survey of glauco-
ma diagnostic and treatment preferences among Latin American 
ophthalmologists. Our study has found a substantial level of agree-
ment among glaucoma specialists in Latin America for most diagnos-
tic and treatment practices surveyed. 
Our survey found consistent agreement among regional spe-
cialists surveyed about the importance of treating to target IOP and 
maintaining a stable IOP over 24 hours, whereas the respondents did 
not agree that the greatest possible decrease in IOP should be sought 
in order to minimize the risk of progression of glaucoma damage. This 
implies that, among two possible strategies for optimizing medical 
Level of agreement among Latin American glaucoma subspecialists on the diagnosis and treatment of glaucoma:  
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Table 2. Diagnosis of glaucoma consensus statements (questions with 70% or greater agreement) 
Question 
No
No of  
responses Summary
n (%)  
responding in 
the affirmative
General concepts 
055 48 Elevated IOP is not essential for diagnosis of POAG 41 (085.4%)
057 48 Blood flow to the optic nerve is important in POAG pathogenesis 35 (072.9%)
052 48 Structural and/or functional signs of damage are essential for diagnosis 44 (091.7%)
054 48 Glaucoma diagnosis requires characteristic change to optic disc or visual field defect 40 (083.3%)
056 48 Lack of defect in achromatic pathway is a requisite for pre-perimetric diagnosis 38 (079.2%)
Clinical examination of the optic nerve
067 48 Advisable to estimate optic disc size biomicroscopically by slit lamp and/or direct ophthalmoscopy 37 (077.1%)
068 48 Loss of shape of neuroretinal ring in normal-sized optic nerve heads is an early sign of glaucoma 42 (087.5%)
073 48 Clinical examination of the optic nerve should include disc size, keeping the ISNT rule, cup-disc ratio, asymmetry in the C-D 
ratio, rim regularity, rim color and cupping, position of the blood vessels, presence of papillary and juxtapapillary hemorrhages, 
peripapillary atrophy and conservation of the nerve fiber layer
43 (089.6%)
059 48 Clinical examination of optic nerve with dilated pupil in slit lamp using indirect magnification is the structural gold standard 
for examining POAG
44 (091.7%)
060 48 Recording the condition of the optic nerve is essential in glaucoma and suspected glaucoma 46 (095.8%)
061 48 Recording of optic nerve condition should be by color spectrophotography, digital photography and/or structural imaging, 
with itemized drawing if other technologies are unavailable
44 (091.7%)
062 48 Photographic documentation is the gold standard for structural evaluation in glaucoma 43 (089.6%)
063 48 Serial photography is the basic minimum structural method of recording progression in POAG 45 (093.8%)
064 48 Examination with indirect vision lenses (90, 78, and 60 diopters) is suitable for clinical evaluation of optic nerve 45 (093.8%)
072 48 Increase with time in area of cupping or cup-disc ratio is important in differentiating normal nerve and glaucoma 47 (097.9%)
074 48 It is advisable to examine the optic nerve’s condition in glaucoma patients at each visit 36 (075.0%)
058 48 An optic nerve examination is essential for the diagnosis and management of glaucoma 45 (093.7%)
065 48 Lenses with higher dioptric power (90D) provide satisfactory viewing in almost all pupil sizes, while the smaller ones, especially 
that of 60D, require mydriasis, or at least that the pupil diameter not be reduced. The latter, however, provide a better view 
of the details of the optic nerve
37 (077.1%)
069 48 Optic disc hemorrhages indicate the presence of glaucoma damage and suggest progression, and are most frequently found 
in normal tension glaucoma
44 (091.6%)
070 48 Early or moderate optic nerve damage can be underestimated in small optical nerves, and a proper diagnosis may not be made 48 (100.0%)
071 48 In large optic nerves, the diagnosis of glaucoma is often overestimated 46 (095.9%)
examination of the nerve fiber layer
075 48 Monitoring the condition of the nerve fiber layer in glaucoma is essential 35 (072.9%)
076 48 Diffuse defects of the nerve fiber layer in OAG are harder to detect than localized defects and are inferred by detailed obser-
vation of the vessels
47 (097.9%)
078 46 Localized defects of the nerve fiber layer are arch-shaped and extend to the edge of the optic disc 41 (085.4%)
Diagnosis in PCAG/gonioscopy
084 48 After the initial examination, gonioscopy should be repeated over time 48 (0100.0%)
082 48 Gonioscopic evaluation is recommended as part of routine eye exam for all patients aged >40 years 34 (070.8%)
085 48 It is useful to adopt a particular gonioscopic-type classification of angle 37 (077.1%)
080 48 Van Herick’s technique for estimating anterior chamber depth is not a substitute for gonioscopy 45 (093.8%)
083 48 Gonioscopy should be performed in all patients with glaucoma or suspected glaucoma 48 (100.0%)
Functional examination
088 48 SAP is the most important functional examination for diagnosis and monitoring of POAG 48 (100.0%)
090 48 Both frequency doubling perimetry and blue on yellow perimetry are useful in detecting functional defects before achromatic 
perimetry is used
39 (081.3%)
102 48 The FDT should be utilized in a glaucoma suspect with normal SAP 37 (077.1%)
087 48 The computerized perimetry examination is essential for the diagnosis of POAG 35 (072.9%)
089 48 A multimodal functional assessment (not perimetry techniques) seems to be most effective in detecting early glaucoma defects 39 (081.3%)
091 48 The functional changes in glaucoma are progressive visual field deterioration and loss of sensitivity to colors 45 (093.8%)
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Table 2. Diagnosis of glaucoma consensus statements (questions with 70% or greater agreement) (continued)
Question 
No
No of  
responses Summary
n (%)  
responding in 
the affirmative
Intraocular pressure
093 48 There are no suitable methods that are proven to be able to correct IOP correctly for corneal thickness 34 (070.8%)
097 48 Longitudinal studies are needed to assess importance of IOP fluctuation over 24 hours 43 (089.6%)
099 48 I request/perform IOP diurnal tension curve 40 (083.3%)
100 43 IOP diurnal tension curves should only be performed in cases of suspected glaucoma 36 (083.7%)
092 48 Central corneal thickness is important in assessment of glaucoma or suspected glaucoma 48 (100.0%)
094 48 Goldmann tonometer is the gold standard for measuring IOP 47 (097.9%)
101 48 The ibopamine test is not essential for the diagnosis of glaucoma 47 (097.9%)
Structural examination by imaging
103 48 Computerized imaging tests help in clinical evaluation of optic disc 48 (100.0%)
106 48 HRT is the structural method with greatest evidence of fitness for analyzing progression of optic nerve head 38 (079.2%)
104 48 Computerized imaging tests in glaucoma help in diagnosis and in longitudinal monitoring 42 (087.5%)
FDT= frequency doubling technology; IOP= intraocular pressure; ISNT= inferior ≥ superior ≥ nasal ≥ temporal; HRT= Heidelberg retinal tomography; OAG= open-angle glaucoma; PCAG= 
primary closed-angle glaucoma; POAG= primary open-angle glaucoma; SAP= standard automated perimetry.
therapy (using target IOP or searching for the lowest possible IOP 
with initial medication), the responders clearly preferred the first one. 
Using target IOP to guide clinical management is a well-established 
practice and one that is supported by the results of large-scale 
studies such as the Collaborative Initial Glaucoma Treatment Study 
(CIGTS)(21). This approach allows treatment to be targeted to the 
individual’s baseline IOP, optic nerve appearance and visual function, 
and to initiate more aggressive treatment at signs of deterioration. 
It also allows physicians and patients to develop a partnership in 
glaucoma management; if patients are aware of the target IOP they 
are trying to reach, they may be more engaged and adherent with 
treatment. While there is clear evidence that the lower the IOP, the 
less the risk of glaucomatous progression, physicians may be reluc-
tant to initiate aggressive therapy because this may limit their future 
treatment options. Physicians may also fear that patients will develop 
adverse effects, potentially impacting their adherence. For some pa-
tients, the aggressive therapeutic options (combination therapy or 
surgery) may be unaffordable, particularly in developing countries. 
These factors probably contributed to the lack of agreement about 
achieving the greatest possible reduction in IOP in our survey. 
Some statements in our survey have important educational im -
plications. For example, the panelists consider it essential for a clinician 
to know the rates of hypotensive efficacy of glaucoma medications. 
They also agreed that a hypotensive effect of less than 10% is unaccep-
table and should prompt substitution with a more effective treatment.
It is also interesting to note that, in a region known historically 
to favor low-cost medications such as β-blockers, the Latin American 
glaucoma specialists in our sample considered prostaglandin analogs 
to be the monotherapy of first choice. This probably reflects the 
respondents’ assessment of drug efficacy and safety rather than affor-
dability, since there was agreement that the cost of medical therapy 
is not affordable for most patients in Latin America (question 42). 
Prostaglandin analogs have demonstrated greater hypotensive effi-
cacy compared with other classes of topical glaucoma therapies(22,23) 
and a low rate of systemic adverse effects, a fact with which the Latin 
American respondents to our survey also showed substantive agree-
ment. The most common adverse event with prostaglandin analogs 
is conjunctival hyperemia, whereas this is less frequent with topical 
β-blockers(24). Latin American physicians agree that topical β-blockers 
have the best ocular safety profile (question 31). Overall, respondents 
believe that hypotensive efficacy with reasonable safety is more 
important than safety alone (question 17). Therefore, taken together, 
the survey findings indicate that Latin American physicians consider 
that the greater efficacy of prostaglandin analogs and their improved 
systemic safety profile outweigh concerns about ocular tolerability. 
Agreement was not reached regarding the number of bottles that 
constitute maximum medical therapy, or on the maximum number 
of instillations compatible with good cooperation with the treat-
ment. Presumably, this reflects the diversity of adherence behavior 
between patients seen in routine clinical practice. 
In our survey, most respondents (70.0%) did not think it was 
important that certain medications (like a fixed combination of 
prostaglandin analog plus β-blocker) have not been approved by 
the US Food and Drug Administration (FDA). This may indicate an 
acceptance of lower standards of rigor in the regulation of phar-
maceutical products in Latin America compared with the US. While 
many survey respondents agreed (59.2%) that generic medications 
were bioequivalent and interchangeable, they also agreed (81.6%) 
that “copy medications” were not. The World Bank has suggested 
that Latin American regulatory agencies are under-resourced, and 
has highlighted differences between countries in both registration 
policies and terminology (including the use of the terms “generic” 
and “bioequivalence”)(25,26). This may have led to different interpreta-
tions of the questions relating to generic medications in our survey 
between respondents from different countries, and contributed to 
the lack of agreement about the bioequivalence of generic and “copy” 
medications (questions 46 and 47).
Regarding the diagnosis of glaucoma, Latin American physicians 
agreed on the need to examine the condition of the optic nerve at 
each visit, consistent with WGA recommendations(13). However, this 
may be an area in which theory falls short of practice, since there are 
data to suggest that, even in developed countries, optic nerve status 
examination and documentation are suboptimal during routine 
clinical practice(27,28). Our survey also found agreement on photogra-
phic documentation as the gold standard for structural evaluation in 
glaucoma and the value of computerized imaging in the evaluation 
of the optic disc. These approaches are also consistent with WGA 
consensus recommendations(13), and can produce more accurate and 
quantitative assessment of structural changes than can be achieved 
with annotated drawings or written chart entries(29). Nevertheless, 
Latin American survey participants agreed that an itemized drawing 
can be a useful resource when technology is unavailable.
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Latin American physicians agreed on the importance of gonios-
copy in first examination for all patients over 40 years to detect the 
presence of CAG, and its repetition over time when examining a CAG 
patient or a CAG suspect. Direct epidemiologic data on prevalence of 
CAG in Latin America are limited. They range from a general estima-
tion of 5.7% of glaucoma cases(1) to 21.4% in one sample from South 
Brazil(30). Unpublished surveys indicate that CAG rates may be high in 
some native ethnic populations within Latin America.
Not surprisingly, no agreement was obtained on the new me-
thods of tonometry such as the Pascal dynamic contour tonometer 
or the ORA. This may reflect a concern among Latin American phy-
sicians that more published evidence and clinical experience with 
these devices are required. However, there was agreement about the 
importance of measuring central corneal thickness in order to gain a 
more accurate assessment of IOP.
A limitation of the present research is that the 107 items in the 
survey could not cover all the issues involving diagnosis and treat-
ment of glaucoma. Although we created the questionnaire based 
on a detailed review of the literature, there may have been other 
relevant topics that were not included. Further investigation, possibly 
including the distribution of a second questionnaire to experts in 
this field, may be needed for further validation. Such a survey could 
also identify any changes over time in the opinions of Latin Ameri-
can ophthalmologists toward optimal practice in the diagnosis and 
management of glaucoma.
CONClUSION
This survey, the largest one to date on diagnosis and therapy of 
glaucoma among Latin American experts, has demonstrated a high 
level of agreement on optimal practices in the diagnosis and medical 
management of glaucoma. There was consensus for more than two- 
thirds of the questions, indicating a high level of agreement across 
the region on evidence-based recommendations. However, many 
barriers toward optimal detection and treatment of glaucoma exist in 
Latin America. The information gained from this survey can be used 
to inform future educational efforts in the region, with the aim of 
further improving glaucoma diagnosis and management. 
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